Thomas Smith
Stock Analyst at Leerink Partners
(2.00)
# 3,118
Out of 5,076 analysts
60
Total ratings
32.08%
Success rate
7.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $42 | $20.91 | +100.86% | 1 | Dec 1, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $31.51 | +17.42% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.86 | +16.28% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.82 | +135.60% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.61 | +168.20% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $7.35 | +294.56% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.30 | +434.25% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.80 | +282.35% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $119.92 | -83.32% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $894.90 | -51.39% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $91.69 | -60.74% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.77 | +152.71% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $22.75 | -7.69% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $31.45 | +43.08% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $13.30 | -54.89% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.43 | +10.50% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.68 | +636.38% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $13.25 | +28.30% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $25.92 | +146.91% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.79 | +316.91% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $1.53 | +1,599.35% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $34.55 | -65.27% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $17.77 | +2,150.98% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $17.18 | +365.66% | 2 | Dec 8, 2020 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $20.91
Upside: +100.86%
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $31.51
Upside: +17.42%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.86
Upside: +16.28%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.82
Upside: +135.60%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.61
Upside: +168.20%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $7.35
Upside: +294.56%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.30
Upside: +434.25%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.80
Upside: +282.35%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $119.92
Upside: -83.32%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $894.90
Upside: -51.39%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $91.69
Upside: -60.74%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.77
Upside: +152.71%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $22.75
Upside: -7.69%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $31.45
Upside: +43.08%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $13.30
Upside: -54.89%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.43
Upside: +10.50%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.68
Upside: +636.38%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $13.25
Upside: +28.30%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $25.92
Upside: +146.91%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.79
Upside: +316.91%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $1.53
Upside: +1,599.35%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $34.55
Upside: -65.27%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $17.77
Upside: +2,150.98%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $17.18
Upside: +365.66%